1. Cancer statistics, 2013;R Siegel;CA Cancer J Clin,2013
2. Driver mutations and differential sensitivity to targeted therapies a new approach to the treatment of lung adenocarcinoma;SR Giuseppe;Cancer Treatment Reviews,2010
3. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers;X Zhou;Clin Cancer Res,2004
4. Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond;N Karachaliou;Cancer Biol Med,2014
5. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine;S Sadeghi;Pharmgenomics Pers Med,2014